Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-009: Olaparib plus pembrolizumab vs chemotherapy plus pembrolizumab after induction in metastatic triple negative breast cancer
jRCT2080224993Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) and breast cancer comparing Pembrolizumab + olaparib with Pembrolizumab + carboplatin + gemcitabine (2 arms). Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Started Dec 2019; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on jRCT2080224993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224993.